Cancer diagnostic firm Caris Life Sciences on Monday raised the proposed price range for its New York initial public offering, targeting a valuation of up to $5.67 billion and indicating a strong ...

Two-thirds of its members rely on Chime as the primary financial relationship. Through its platform, members deposit their ...

Stocks of newly-public companies are surging in their first sessions at the fastest pace in three and a half years, ...